Jane L. Liesveld

14.5k total citations · 1 hit paper
252 papers, 8.3k citations indexed

About

Jane L. Liesveld is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Jane L. Liesveld has authored 252 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 143 papers in Hematology, 69 papers in Oncology and 64 papers in Molecular Biology. Recurrent topics in Jane L. Liesveld's work include Acute Myeloid Leukemia Research (85 papers), Hematopoietic Stem Cell Transplantation (56 papers) and Lymphoma Diagnosis and Treatment (29 papers). Jane L. Liesveld is often cited by papers focused on Acute Myeloid Leukemia Research (85 papers), Hematopoietic Stem Cell Transplantation (56 papers) and Lymphoma Diagnosis and Treatment (29 papers). Jane L. Liesveld collaborates with scholars based in United States, France and Australia. Jane L. Liesveld's co-authors include Michael W. Becker, Craig T. Jordan, Camille N. Abboud, Kristen M. O’Dwyer, Randall M. Rossi, John M. Ashton, Camille N. Abboud, Louis S. Constine, Kevin P. Callahan and Eleni D. Lagadinou and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jane L. Liesveld

242 papers receiving 8.1k citations

Hit Papers

BCL-2 Inhibition Targets ... 2013 2026 2017 2021 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
    2013 943 citations John M. Ashton, Kristen M. O’Dwyer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jane L. Liesveld United States 47 3.7k 2.8k 2.3k 1.6k 1.4k 252 8.3k
Rainer Haas Germany 55 6.1k 1.6× 3.0k 1.1× 2.6k 1.1× 1.6k 1.0× 2.3k 1.6× 367 10.2k
Christian Chabannon France 44 3.7k 1.0× 1.7k 0.6× 2.8k 1.2× 2.8k 1.7× 921 0.7× 299 8.0k
Meir Wetzler United States 48 5.0k 1.3× 3.0k 1.1× 2.1k 0.9× 1.1k 0.7× 2.1k 1.5× 245 8.6k
Kevin Shannon United States 58 3.7k 1.0× 6.2k 2.2× 2.2k 1.0× 1.6k 1.0× 1.7k 1.2× 276 12.5k
Kimmo Porkka Finland 52 3.2k 0.9× 3.5k 1.3× 1.5k 0.6× 1.2k 0.7× 2.5k 1.8× 231 9.9k
Charlotte M. Niemeyer Germany 54 4.8k 1.3× 4.1k 1.5× 1.6k 0.7× 2.1k 1.3× 1.8k 1.3× 260 10.3k
Seema Singhal United States 50 7.0k 1.9× 4.6k 1.6× 4.0k 1.7× 1.1k 0.7× 1.3k 0.9× 291 10.7k
Sonja Zweegman Netherlands 55 6.5k 1.7× 5.1k 1.8× 4.6k 2.0× 1.5k 0.9× 1.5k 1.1× 334 10.4k
Tim H. Brümmendorf Germany 46 4.3k 1.1× 2.9k 1.0× 1.6k 0.7× 1.1k 0.7× 3.4k 2.5× 298 9.0k
Robert Zeiser Germany 56 4.5k 1.2× 2.8k 1.0× 2.8k 1.2× 5.2k 3.2× 1.2k 0.9× 287 11.4k

Countries citing papers authored by Jane L. Liesveld

Since Specialization
Citations

This map shows the geographic impact of Jane L. Liesveld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane L. Liesveld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane L. Liesveld more than expected).

Fields of papers citing papers by Jane L. Liesveld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane L. Liesveld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane L. Liesveld. The network helps show where Jane L. Liesveld may publish in the future.

Co-authorship network of co-authors of Jane L. Liesveld

This figure shows the co-authorship network connecting the top 25 collaborators of Jane L. Liesveld. A scholar is included among the top collaborators of Jane L. Liesveld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane L. Liesveld. Jane L. Liesveld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chaves, Francisco A., Yi Zhang, Richard Burack, et al.. (2025). Apolipoproteins from the microenvironment promote aggressive myeloid leukemia progression. Blood. 146(Supplement 1). 3186–3186.
2.
Baran, Andrea, et al.. (2024). Portable Medical Orders and Inpatient Cost at End of Life in Acute Myeloid Leukemia and Myelodysplastic Syndromes. JCO Oncology Practice. 21(6). 876–882. 1 indexed citations
3.
4.
Mendler, Jason H., Sally A. Norton, Rachelle Bernacki, et al.. (2024). Clinicians’ Perspectives on the Telehealth Serious Illness Care Program for Older Adults With Myeloid Malignancies: Single-Arm Pilot Study. JMIR Formative Research. 8. e58503–e58503.
5.
6.
Fucile, Christopher, Michael S. Piepenbrink, Catherine A. Bunce, et al.. (2023). Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans. AIDS Research and Human Retroviruses. 39(7). 350–366. 2 indexed citations
7.
Liesveld, Jane L., et al.. (2022). The therapeutic potential of bedside art observation in hematologic cancer inpatients: a randomized controlled pilot study. Supportive Care in Cancer. 30(4). 3585–3592. 4 indexed citations
8.
9.
Baran, Andrea, et al.. (2021). Targeted therapy for treatment of patients with classical hairy cell leukemia. Leukemia Research. 102. 106522–106522. 7 indexed citations
10.
Azadniv, Mitra, Jason R. Myers, Helene R. McMurray, et al.. (2019). Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia. 34(2). 391–403. 71 indexed citations
11.
Loh, Kah Poh, Erika Ramsdale, Eva Culakova, et al.. (2018). Novel mHealth App to Deliver Geriatric Assessment-Driven Interventions for Older Adults With Cancer: Pilot Feasibility and Usability Study. JMIR Cancer. 4(2). e10296–e10296. 50 indexed citations
12.
Ho, Tzu‐Chieh, Mark W. LaMere, Brett M. Stevens, et al.. (2016). Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 128(13). 1671–1678. 166 indexed citations
13.
Hunter, Bradley D., Megan M. Herr, Ferdous M. Barlaskar, et al.. (2016). Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma & Leukemia. 17(3). 145–151. 9 indexed citations
14.
Balderman, Sophia, Allison J. Li, Corey M. Hoffman, et al.. (2015). Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. Blood. 127(5). 616–625. 67 indexed citations
15.
Hassane, Duane C., Mónica L. Guzmán, Cheryl A. Corbett, et al.. (2008). Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111(12). 5654–5662. 145 indexed citations
16.
Mendler, Jason H., Jennifer L. Kelly, Susan Voci, et al.. (2008). Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology. 19(10). 1759–1764. 28 indexed citations
17.
Liesveld, Jane L., et al.. (2007). Investigating the Feasibility of Stem Cell Enrichment Mediated by Immobilized Selectins. Biotechnology Progress. 23(6). 1463–1472. 23 indexed citations
18.
Liesveld, Jane L., et al.. (2001). Response of Human CD34 + Cells to CXC, CC, and CX 3 C Chemokines: Implications for Cell Migration and Activation. Journal of Hematotherapy & Stem Cell Research. 10(5). 643–655. 21 indexed citations
19.
Liesveld, Jane L., et al.. (1995). Effect of stem cell factor on myelopoiesis potential in human Dexter-type culture systems.. PubMed. 23(3). 202–9. 10 indexed citations
20.
Liesveld, Jane L., Peter C. Keng, Jacob M. Rowe, John F. DiPersio, & Camille N. Abboud. (1994). Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. Leukemia Research. 18(8). 609–616. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rainer Haas Breakdown of academic impact, for papers by Christian Chabannon Breakdown of academic impact, for papers by Meir Wetzler Breakdown of academic impact, for papers by Kevin Shannon Breakdown of academic impact, for papers by Kimmo Porkka Breakdown of academic impact, for papers by Charlotte M. Niemeyer Breakdown of academic impact, for papers by Seema Singhal Breakdown of academic impact, for papers by Sonja Zweegman Breakdown of academic impact, for papers by Tim H. Brümmendorf Breakdown of academic impact, for papers by Robert Zeiser
Rankless by CCL
2026